Around the world, researchers are working extremely hard to develop new treatments and interventions for COVID-19 with new clinical trials opening nearly every day. This directory provides you with information, including enrollment detail, about these trials. In some cases, researchers are able to offer expanded access (sometimes called compassionate use) to an investigational drug when a patient cannot participate in a clinical trial.
The information provided here is drawn from ClinicalTrials.gov. If you do not find a satisfactory expanded access program here, please search in our COVID Company Directory. Some companies consider expanded access requests for single patients, even if they do not show an active expanded access listing in this database. Please contact the company directly to explore the possibility of expanded access.
Emergency INDs
To learn how to apply for expanded access, please visit our Guides designed to walk healthcare providers, patients and/or caregivers through the process of applying for expanded access. Please note that given the situation with COVID-19 and the need to move as fast as possible, many physicians are requesting expanded access for emergency use. In these cases, FDA will authorize treatment by telephone and treatment can start immediately. For more details, consult FDA guidance. Emergency IND is the common route that patients are receiving convalescent plasma.
Search Tips
To search this directory, simply type a drug name, condition, company name, location, or other term of your choice into the search bar and click SEARCH. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (e.g., “acute respiratory distress syndrome” or “ARDS”). You may opt to further streamline your search by using the Status of the study and Intervention Type options. Simply click one or more of those boxes to refine your search.
Displaying 200 of 245University of Oxford
A phase I/II single-blinded, randomised, multi-centre study to determine efficacy, safetyand immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1nCoV-19 in UK healthy adult volunteers aged 18-55 years. The vaccine will be administeredintramuscularly (IM) into the deltoid region of the arm
Mayo Clinic
Researchers are creating a real time COVID-19 registry of current ICU/hospital carepatterns to allow evaluations of safety and observational effectiveness of COVID-19practices and to determine the variations in practice across hospitals.
Universitaire Ziekenhuizen KU Leuven
The COntAGIouS trial (COvid-19 Advanced Genetic and Immunologic Sampling; an in-depthcharacterization of the dynamic host immune response to coronavirus SARS-CoV-2) proposesa transdisciplinary approach to identify host factors resulting in hyper-susceptibilityto SARS-CoV-2 infection, which is urgently needed for directed medical interventions.
Stanford University
The purpose of this study is to understand the impact of COVID-19 on patients with cancerthrough a survey.
Queen Mary University of London
COVIDENCE UK is a population-based observational longitudinal study that has thefollowing objectives: 1. To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population 2. To characterise the natural history of COVID-19 in the UK population 3. To evaluate the impact of COVID-19 on the physical and mental health of the UK population 4. To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in COVIDENCE as comparison or control data for trial participants who have been randomised to receive one or more interventions.
University Hospital, Bordeaux
The coronavirus disease 2019 (COVID-19) outbreak is now considered as a public healthemergency of international concern by the World Health Organization.In the context of the health emergency, research on the pathogen (the SARS-CoV-2coronavirus), the disease and the therapeutic care is being organized. Research projectsrequire the use of biological samples. This study aims at setting up a collection ofbiological samples intended for application projects in any discipline.The main objective of the study is to collect, process and store biological samples frompatients and caregivers infected with SARS-CoV-2 (COVID-19) at the biological ressourcescenter of the Bordeaux University Hospital.
University Hospital, Akershus
Prospective cohort study of COVID-19 infection among children in Norway.
DSCS CRO
This is a Phase II interventional study testing whether treatment withhydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19
Rutgers, The State University of New Jersey
Our long-term goal is to protect the health care workforce (HCW) caring forSARS-CoV-2-infected patients, their families, communities, and the general population.Our specific objective is to rapidly establish a prospective cohort to characterize thefactors related to viral transmission and disease severity in a large healthcare system.We addressed this hypothesis by recruiting and longitudinally following 546 HCW and acomparison group of 283 non-HCW within a large academic health system, Rutgers Biomedicaland Health Sciences (RBHS). By intensively following participants over a several yearperiod (2020-2024) and collecting serial biospecimens (nasopharyngeal/throat swabs,blood, and saliva) and questionnaire data at multiple time points, we will uniquelycharacterize SARS-CoV-2 transmission and risk factors for COVID-19 among HCW and ourlarger academic community.
University Hospital, Toulouse
The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viralpneumopathy that can progress to acute respiratory distress syndrome (ARDS). Thehost-pathogen relationships and the physiopathological mechanisms underlying the clinicalaggravation of COVID-19 patients remain misunderstood. The project aim is to create aprospective cohort of biological samples collected from well characterized COVID-19patients. This project aims first to identify based on these samples an early immunesignature predictive of clinical worsening of COVID-19 patients in order to improve theirmanagement, and secondarily to better understand pathophysiological mechanisms underlyingthe different phases of the disease in order to identify innovative therapeutic targetsand vaccine perspectives.